bluuebunny/crossref_metadata_2025_split huggingface dataset:
Differential expression proteins in lung adenocarcinoma with bone metastasis: Correlation of ALDH2 and ENO1 with prognosis.
Authors: Yang Mengdi , Sun Jing , Wang Zhiyu , Zhang Rui , Gu YIfeng , Zhao Hui 
Published: September 2018

e20534 Background: The prognosis of lung adenocarcinoma (LUAD) with bone metastases (BM) is still poor. It is increasingly demanded to find key proteins to solve the problem. Methods: First, we collected three groups of bone tissues: normal, osteosarcoma, and LUAD with BM from Shanghai Sixth People's Hospital. Each group had five patients. Two-dimensional gel electrophoresis (2D-E) was used to find proteins with significant differences, then Maldi-tof-tof mass spectrometry was used to identify the proteins. Second, immunohistochemical (IHC) was used to check the expression of proteins in 28 BM patients and 9 LUAD patients. Real-Time PCR (QPCR), western boltting (WB) were further used to check the expression of para-LUAD, LUAD and BM. Last, we downloaded RNA-seq and clinical datas from the Cancer Genome Atlas(TCGA) database to further verify differentially expressed genes using ‘DESeq’ package and explored their relationship with survival using ‘survival’ package in R. Kaplan-Meier survival plot and the hazard ratio and logrankp was calculated (www.kmplot.com/lung). Results: We got 26 matched proteins from 2D-E, then selected Aldehyde Dehydrogenase 2 Family (Mitochondrial) (ALDH2) and Enolase-1 (ENO1). In IHC analysis, strong-stained ALDH2 showed OR = 0.568 (95 % confidence interval [CI], 0.317-1.019), p= 0.036, strong-stained ENO1 OR = 1.929 (95% CI, 0.915-4.066), p= 0.023, were associated with bone metastastic incidences in LUAD with statistically significantly difference. QPCR, WB validated that ALDH2 had lowest expression in BM, followed by LUAD samples, and para-LUAD highest. However, ENO1 displayed the opposite tendency . In TCGA LUAD RNA-seq, ALDH2 had low expression ( p= 3.83E-12, log2Foldchange = 1.158), and ENO1 was up-regulated ( p= 0.0004, log2Foldchange = 1.210 ). ALDH2 is correlated with better survival (HR = 0.47, 95% CI (0.37-0.61), logrankP = 6.5E-10), while ENO1 was inversely associated with better prognosis (HR = 1.67,95% CI (1.32-2.12), logrankP = 1.9E-05) in K-M Plotter. Conclusions: In this study, we discovered new differential expression and prognosis related proteins, ALDH2 and ENO1, and they are worthy of further exploration into the underlying mechanism.
Retrospective review of concurrent chest radiation and chemotherapy (CRT) in newly diagnosed stage IV non-small cell lung cancer (NSCLC) with oligometastatic disease (OM) treated with stereotactic radiation.
Authors: Narayan Preeti , Yeung Anamaria R , Ogunlari Olushola , Morris Chris G , Gopalan Priya Kadambi 
Published: September 2018

e20539 Background:The primary treatment for patients (pts)with stage IV NSCLC is palliative chemotherapy (CT), with a median OS of approximately 10-12 months, and 5-year survival of ~2%. Several studies have demonstrated that pts with a lung nodule with a solitary brain or adrenal metastasis can achieve relatively high 5-year survival rates with resection of the metastasis and the lung nodule. Studies have also demonstrated that OM can be effectively treated with stereotactic body radiation (SBRT) or stereotactic radiosurgery (SRS) to the brain. We hypothesize that treatment of OM with SBRT and/or SRS and treatment of the thoracic disease with CRT will improve survival over palliative chemotherapy alone. Methods:A retrospective review of charts in the RADTRACS database at the Univ of Florida was conducted between 1/1/2010 - 6/30/2015 to identify pts with newly diagnosed stage IV NSCLC with 5 or less OM at diagnosis that were treated with concurrent CT and definitive RT (60-66 Gy) to the primary lung mass in addition to SRS and/or SBRT to the OM. Date and site of first progression, and date of death/last follow-up were noted. Endpoints included median progression free survival (PFS) and median overall survival (OS). Results:26 pts met these criteria. 20 pts (77%) had recurrence of disease after treatment with CRT + SRS/SBRT. Median PFS was 6 months, and median OS was 14.4 months. Of the 20 recurrences, 10 (50%) were in the brain, while 10 (50%) were in non-CNS sites. One year OS was 60% and 3-year survival was 33% in our patients. When pts with CNS OM at diagnosis were compared to non-CNS OM, PFS (5.5 vs 5.8 months, respectively, p > 0.05) and OS (16.6 vs 13.8 months, respectively, p > 0.05) were similar. 8/12 CNS OM pts progressed in the brain while only 3/9 non-CNS OM progressed in the brain. Of the 5 patients with no progression, 4/5 had non-CNS OM at diagnosis. Conclusions:When compared to standard palliative CT where median OS 10-12 months, median OS was 14.4 months in our pts treated with CRT + SBRT/SRS. This data suggests a possible role for more aggressive treatment of stage IV NSCLC pts with SBRT/SRS to OM and definitive chest CRT.
LuCaS (Lung Cancer Surveillance) study: Surveillance models for advanced lung cancer patients.
Authors: Fraser Sarah Anne 
Published: September 2018

e20546 I hope to present the trial protocol as a poster at ASCO with co design work commencing 2017. Background: Lung cancer is the leading cause of cancer death in NZ.1 85% of registrations annually are stage four at diagnosis, presenting a significant burden on resources. Despite novel therapies, survival is poor and quality of life is a key consideration in patient management .2,3 Currently the aim of surveillance is to detect for disease progression and follows a three monthly pattern. There is little literature around benefits of surveillance on survival, and quality of life in these patients. 4-6 Alternative approaches to surveillance should be evaluated to ensure safe, convenient, economical care. Lung cancer outcomes for Maori patients sit significantly lower than those for New Zealand Europeans. Maori patients are twice as likely to present with locally advanced disease and four times less likely to receive curative treatment (multivariate analysis). There are significant barriers for Maori patients to attending health care including time off work, health literacy, costs, child care, language barriers, and transport. 19 Ministry of Health data describes poor outcomes for Maori lung cancer patients with rate of death sitting at 3.4 times that of non-Maori. Co-Primary End Points To determine if there is a reduction in health services utilisation (ED visits, hospital visits, unplanned clinic visits, GP visits, and Nurse Specialist contact) with the end point identified at progression, lost to follow up, or death. To compare the impact of a novel virtual surveillance model (VSM) versus usual follow-up care on patient anxiety measured using the HADS-A tool. Methods: LuCaS is a Randomised Controlled trial in patients with advanced lung cancer randomised to virtual model or standard care. Results: recruitment begins this year. Conclusions: Hypothesis:A virtual follow up model for advanced stage non-small cell lung cancer patients, extensive stage small cell lung cancer patients, and mesothelioma patients will reduce health care utilisation and patient experienced anxiety defined by reduction in Hospital Anxiety and Depression Scale (HADS-A) score, while maintaining effectiveness detecting recurrence and survival.
The efficiency of apatinib plus S-1 as second-line or laterline chemotherapy for advanced non-small-cell lung cancer.
Authors: Wu Zhiyong , Wu Jianyu , Dai Guanghai , Si Haiyan , Wang Yanrong , Zhao Haiqing , Wang Guanqing , Cao Hongli 
Published: September 2018

e20549 Background: There is no standard treatment strategy for patients with advanced non-small cell lung cancer (NSCLC) who experienced progression with three or more lines of chemotherapy. Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2), has been shown confirming antitumor activity and manageable toxicities in breast and gastric cancers. Clinical trials of apatinib on non-small cell lung cancer show that progression-free survival is improved, but the objective response rate is still low. However, It remains to be explored whether the combined treatment of apatinib plus S1 could be further effective on NSCLC. Methods: We retrospectively assessed the efficacy and safety of apatinib plus S1 in patients with advanced NSCLC after the failure of second or third-line chemotherapy. The study group comprised 12 patients who received oral apatinib, at a dose of 250 mg daily, and S1, at a dose of 40-60mg bid D1-14, repeat every 3 weeks, for progression after the failure of second or third-line chemotherapy for advanced NSCLC. Treatment was continued until disease progression. Results: Between Mar 30, 2016 and Feb 1, 2017, 12 patients were enrolled. In 12 patients, there were 10 patients available for efficacy and safety evaluation. 4/10 (40%) patients experienced dose reduction during treatment. Followed up to Feb 1, 2016, the median during time of treatment was 3 months. According to RECIST criteria, the disease control rate was 80%, 8/10 (partial response 50%, 5/10 and stable disease 30%, 3/10). The most frequent treatment-related adverse events were secondary hypertension (40%, 4/10), oral mucositis (40%, 4/10), hand-foot syndrome (30%, 3/10) and fatigue (30%, 3/10). Main grade 3 or 4 toxicities were hypertension (20%, 2/10), oral mucositis (10%, 1/10) and fatigue (10%, 1/10). Conclusions: Apatinib plus S1 exhibits superior activity and acceptable toxicity for the heavily pretreated patients with advanced non-small cell lung cancer.
Smoking cessation counseling in advanced non-small cell lung cancer (aNSCLC).
Authors: Radtchenko Janna , Feinberg Bruce A. 
Published: September 2018

e20551 Background: Lung cancer is the leading cause of cancer mortality, with smoking the major risk factor1. Advances in treatment (tx) are lengthening survivorship increasing the importance in smoking cessation among diagnosed pts. Barriers to counseling include: time, skill, patient motivation, prognosis and short survival2. This study analyzed smoking status and cessation counseling in better prognosis aNSCLC patients (pts) defined as those who completed at least two lines of systemic therapy (2L). Methods: Using Inovalon’s MORE2 Registry®claims data for July 2013–2014, pts with aNSCLC identified by ICD-9 codes and treated with chemotherapy (chemo) or targeted therapy (TT; erlotinib, ceritinib, afatinib, or crizotinib) were selected. Pts >18 years of age and treated with 1L therapy within 6 months of diagnosis and who completed 2L were eligible. Pts with small cell lung cancer or secondary malignancies, or pts enrolled in a trial, were ineligible. Smoking history was assessed based on ICD-9 codes (305.1, 649.0, 989.84, V15.82), cessation drug use (bupropion, varenicline, nicotine gum or patches), counseling procedure codes (99406, 99407, G0436, S9453). Results: Of 5,319 pts, 2,198 completed 2L; of those 241 (11%) received 1L TT and 1,957 (89%) 1L chemo. 1L TT had a higher proportion of females (66% vs. 52%, p<0.0001) and a lower smoking rate (33% vs. 58%, p<0.0001) compared to chemo. Cessation rates (counseling or drug) were 9% for 1L TT and 13% for 1L chemo. Conclusions: RWE assessment of smoking incidence and cessation counseling is feasible. Despite methodological limitations one third pts on 1L TT had smoking documentation. Evidence of smoking cessation was present in 12% of pts irrespective of 1L tx choice. Our findings warrant increased focus on smoking cessation in aNSCLC. [Table: see text]
Lymphocytes and neutrophils count after two cycles and TTF1 expression as early outcome predictors during immunotherapy (IT) in stage IV non-small cell lung cancer (NSCLC) patients.
Authors: Baraibar Iosune , Oroz Ricardo , Roman Marta , Martin Patricia , Ponz-Sarvisé Mariano , Rolfo Christian Diego , López-Picazo José María , Perez-Gracia Jose Luis , Gurpide Alfonso , Sala Elarre Pablo , Gil-Bazo Ignacio 
Published: September 2018

e20553 Background: NSCLC therapeutic paradigm has changed with immune checkpoint blockers. Biomarkers predicting clinical benefit are still lacking. As previously shown in melanoma, changes in absolute lymphocytes and neutrophils count (ALC and ANC) during IT (PD-1/PD-L1 inhibitors) may be related to response in NSCLC (Nakamuta et al, Oncotarget 2016). TTF1 expression has been associated with PD-L1 expression (Vieira et al, Lung Cancer 2016). We aimed to investigate TTF1 expression and changes in ALC and ANC after 2 cycles and their potential association with clinical outcomes to IT. Methods: We retrospectively analyzed 26 consecutive patients with stage IV NSCLC treated with IT at Clínica Universidad de Navarra (Spain) during 2016. Radiological response was evaluated according to RECIST v1.1. The potential correlation between ALC and ANC changes during the first two cycles and response to treatment [disease control rate (DCR) vs progression] was evaluated using Student’s T-test. Fisher’s exact test was used to study the association between changes in ALC ( < 1,000 vs > 1,000) and ANC ( < 4,000 vs > 4,000) after 2 cycles and response to IT. TTF-1 expression was correlated with treatment response. Overall survival (OS) was assessed with Kaplan-Meier analysis and Log-rank test according to ALC and ANC. Results: An ALC increase after 2 cycles was significantly associated with DCR compared to progression (192 vs -155; p = 0.043). ALC > 1,000 after 2 cycles was more frequent among patients experiencing DCR compared to progression (87% vs 50%; p = 0.07). ALC > 1,000 after 2 cycles was more frequently observed among patients with TTF1+ tumors (93% vs 55%; p = 0.03). Patients with ANC < 4,000 showed a longer median OS (NR vs 19.25 months; p = 0.03). TTF1 expression in adenocarcinoma (n = 18) was associated with response to IT (83% vs 16%, p = 0.01). Conclusions: Despite this retrospective small series’ limitations, our results show that ALC and ANC changes during IT and TTF1 expression may act as early predictors of clinical benefit in stage IV NSCLC patients treated with PD1/PD-L1 blockers. Our results warrant further investigation in larger prospective series.
FDG-PET in the assessment of metabolic response in patients with NSCLC treated with nivolumab: Preliminary results.
Authors: Goldfarb Lucas , Duchemann Boris , Chouahnia Kader , Gomez Lea , Pop Gabriel , Zelek Laurent , Soussan Michael 
Published: September 2018

e20554 Background: Immunotherapy becomes a standard treatment in non-small-cell lung carcinoma (NSCLC), locally advanced or metastatic, after prior chemotherapy. Because of systemic involvement and heterogeneity of the tumoral disease, methods of assessment are complex and the role of PET-FDG is not well established. The objective of the present study is to describe the results of FDG-PET in the evaluation of patients with NSCLC treated with checkpoint inhibitor (OPDIVO®, Nivolumab) in our academic center. Methods: A retrospective analysis of FDG-PET’s data was performed in 16 patients (performance status: 1), with NSCLC (13 adenocarcinoma, 2 squamous cell carcinoma and 1 large cell neuroendocrine carcinoma) and progression after at least one line of treatment, and treated with Nivolumab. All patients had an FDG-PET before and at 2 months (M2) of treatment. Patients showing progression at M2 had a third PET at M3 to confirm disease progression. Disease responses were assessed according to PERCIST criteria. Patients were considered as responders to Nivolumab treatment, if the treatment was pursued at least 6 months, or as non-responders if the treatment was pursued less than 6 months. Pseudoprogression was defined as a disease progression at M2, which was not confirmed on FDG-PET control at M3. Results: Assessment by FDG-PET after 2 months of treatment showed 8/16 partial metabolic responses (PMR), 6/16 progressive diseases (PD), 1/16 stable disease (SD) and 1/16 complete metabolic response (CMR). Among the patients with PMR, SD or CMR at M2 (n = 10), 90% (9/10) were considered as responders and 10% (1/10) as non-responder. Nivolumab was discontinued in patients with PD. One patient showed a pseudo progression at M2 (PMR at M3), and was eventually classified as non-responder. Conclusions: These results show an association between the metabolic response at M2 and the continuation of the treatment with Nivolumab in NSCLC patients. 90% of patients with early metabolic response showed a sustained response with Nivolumab. FDG-PET could be helpful in the therapeutic strategy of these patients and deserves to be assessed in prospective trials including a cost/benefit evaluation.
Immuno-related cutaneous adverse events (IRcutAEs) of anti-PD-1/anti-PD-L1 therapy in patients (p) with advanced non-small cell lung cancer (NSCLC): A single-institution prospective study.
Authors: Felip Eudald , Garcia Juan Jose , Rivera Noelia , Angelats Laura , Moran Teresa , Erasun Carlos , Vilà Laia , Hardy Max , Gil Maria de los Llanos , Boada Aram , Carcereny Enric 
Published: September 2018

e20556 Background: Despite the impressive benefits of the immune checkpoint blockade in NSCLC, its use can be hampered by the occurrence of serious adverse events. IRcutAEs are underestimated and poorly described according to data from the clinical trials. We sought to characterize the IRcutAEs and their treatment in p with NSCLC. Methods: Before starting immunotherapy, all NSCLC p were prospectively referred to the Dermatology Department. Periodic monitoring visits were also scheduled for each p, in order to describe the IRcutAEs and their treatments. The study included data from all consecutive NSCLC p treated with immunotherapy in our institution. Results: Since May 2016, 50 p were recruited for the present study. According to clinical characteristics; 18 p had squamous histology, 43 p received treatment as second line or further, and 36 p were treated with nivolumab. During the follow-up period, 15 p (30%) developed IRcutAEs. Lichenoid reactions were the most common AE (9 p, 60%), but some specific conditions were also observed, such as a cutaneous lupus (1 p, 6.6%) or an eruptive pseudoangiomatosis (1 p, 6.6%). Conclusions: IRcutAEs are common during antiPD1-PDL1 therapy. By offering a dermatological follow-up, the diagnosis and management of this type of toxicity can be provided to NSCLC p initiating immunotherapy.
The comparison of 18F-alfatide PET/CT and 18F-FDG PET/CT in predicting chemoradiotherapy sensitivity in patients with advanced non-small cell lung cancer.
Authors: Luan Xiaohui , Huang Yong , Liu Ning , Gao Song , Zheng Jinsong , Yu Qingxi , Zhao Shuqiang , Hu Chen , Yu Jinming , Yuan Shuanghu 
Published: September 2018

e20558 Background: Both 18F-alfatide positron emission tomography/computed tomography(PET/CT) and 18F-fluorodeoxyglucose (18F-FDG) PET/CT were potential in predicting thearapy sensitivity, in this study,we recruited patients with advanced NSCLC to detect and compare the potential predictive vaue of them on the CRT sensitivity of patients with advanced non-small cell lung cancer (NSCLC). Methods: According to the design of Natural Science Foundation ofChina (NSFC) 81372413, twenty-four patients with advanced NSCLC accepted 18F-alfatide PET/CT before radiotherapy (T1), another thirty-nine patients underwent 18F-FDG PET/CT at both T1 and during CRT (40Gy of radiotherapy, T2). Logistic regression analyse was used to evaluate the correlations between PET parameters and CRT sensitivity providing an odds ratio (OR), 95% confidence interval (CI) and p value. Propensity score matching (PSM) approach was used to control confounding. Results: Logistic regression analyse showed that Karnofsky Performance Status (KPS) score was correlative with CRT sensitivity. After PSM, controlling KPS scores, twenty-four pairs of patients were matched. The results showed that SUVmax obtained from baseline 18F-alfatide PET/CT was associated with CRT sensitivity in both univariate and multivariable logistic regression analysis (OR: 0.532, 95% CI: 0.305–0.927, p = 0.026; OR:0.376, 95% CI: 0.165-0.860, p = 0.021), but the baseline 18F-FDG PET/CT was not. Univariate analyses showed that the percent change in MTV of 18F-FDG PET/CT between T1 and T2 was correlative with CRTsensitivity (OR: 1.039, 95% CI: 1.003-1.077, p = 0.036). When patients’ KPS score was considered simultaneously, it was still related to CRT sensitivity (OR:1.038, 95% CI: 1.001-1.077, p = 0.045). Conclusions: 18F-alfatidePET/CT may be better than 18F-FDG PET/CT in predicting CRT sensitivity, and 18F-FDG PET/CT is potential in monitoring the tumor response to CRT in patients with advanced NSCLC.
The real-world experience with nivolumab in previously treated patients with advanced non small cell lung cancer (NSCLC): A Galician Lung Cancer Group clinical practice.
Authors: Areses MC , Campelo Rosario Garcia , García González Jorge , Afonso Francisco Javier , Lazaro Martin Emilio , Campos Begoña , Azpitarte Cristina , Amenedo Margarita , Santomé Lucía , Ron David Arias , Alonso-Jaudenes Guillermo , Baron Francisco , Vilchez Rocio , Casal Joaquin , Fernandez Natalia , Carou Iria , Mosquera Joaquin , Anido Urbano , Garcia Mata Jesus , Firvida Jose-luis 
Published: September 2018

e20564 Background: Nivolumab, was the first checkpoint inhibitor to show a survival benefit in previously treated patients with advanced NSCLC in two randomized trials (CheckMate 017 and 057). Experience in routine clinical practice may differ from that seen in a controlled clinical trial. This is an observational study that represents the real-world experience. Methods: Elegibility criteria included, histologically confirmed NSCLC stage IIIB vs IV, evaluable disease and at least one prior therapy. Patients received nivolumab 3 mg/kg IV (60 min) every 2 weeks until progressive disease or unacceptable toxicity. The aim of the study was to report the efficacy and safety profile of Nivolumab in pretreated patients with advanced NSCLC of our everyday clinical practice. The exploratory assessments include response rate (RR), progression-free survival (PFS), overall survival (OS) and treatment related adverse events (AEs). Results: From August 2015 to January 2017, with a median follow time of 18 months, 188 patients were enrolled from 9 different centers. Patients demographics were: median age 62 years, 44 female and 144 male; 17 never smoker and 171 former or current smoker; 105 adenocarcinoma, 7 large-cell carcinoma, 66 squamous, 3 adenosquamous and 7 NSCLC; 61 stage IIIB and 129 stage IV; 42 with central nervous system metastasis; and 70 received 2 or more prior therapy lines. Among 156 patients evaluated, 1,3% had CR, 28,2% PR, 29,7% SD and 40,8% PD. At the time of database lock, the median of PFS was 2.9 IC 95% (2,3-3.4) and OS was 12,8 IC 95% (9,2-16,4). The evaluation of PFS and OS by baseline characteristics doesn´t revealed statistical significance. Grade 1-2 treatment related adverse events (AEs) occurred in 58% of the patients: asthenia (22%), rash (14%), diarrhea (8%), anorexia (7%), endocrine (6%) and neumonitis (1,5%). Grade 3-4 AEs occurred in 5 patients; (3) diarrhea and (2) neumonitis and there were 3 treatment-related deaths. Conclusions: This study represents the real-word experience with nivolumab and the results are consistent with those previously reported in the CheckMate 017 and 057 trials.